AstraZeneca launches new combination medicine in U.S.

AstraZeneca today announced the availability of DUTOPROL™ (metoprolol succinate extended release/hydrochlorothiazide) Tablets in the U.S.

“We have launched DUTOPROL so patients now have the option to receive a branded combination medicine, in a convenient, once-a-day tablet,” said Steve Davis, Executive Director, Foundation Brands, AstraZeneca.

Instead of a traditional payer contracting strategy, AstraZeneca has taken a novel approach in launching DUTOPROL at a wholesale acquisition price ($15.90) that’s competitive to the generics of TOPROL-XL® (metoprolol succinate) extended-release tablets and hydrochlorothiazide tablets, with or without insurance coverage.

AstraZeneca has created DUTOPROL Direct, a direct-to-patient mail-order program, which may offer additional savings to patients beyond the retail pharmacy price so they can fill their prescription for $18.33 per month, with free shipping and handling, when they order a 90-day supply.

DUTOPROL Direct is the second direct-to-patient program from AstraZeneca, which announced a direct-to-patient program for ARIMIDEX® (anastrazole) Tablets in February 2012.  Davis points to both programs as representative of the company’s commitment to find ways to ensure patients have access to, and can afford, the medicines they need to treat their conditions.

For more information on DUTOPROL or how to enroll in DUTOPROL Direct, click on the attached press release.

Please see full Prescribing Information for DUTOPROL and for TOPROL-XL, including Boxed WARNING regarding abrupt cessation of therapy.

DUTOPROL is a trademark and TOPROL-XL and ARIMIDEX are registered trademarks of the AstraZeneca group of companies.

-By Anna Padula, Senior Manager for Brand Corporate Affairs at AstraZeneca

1693006 4/12